COX

Shop By

Items 101-150 of 317

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. COX-2 Specific Inhibitor

    SC-236 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 10 nM and also acts as a PPARγ agonist. It effectively suppresses activator protein-1 (AP-1) through the inhibition of c-Jun NH2-terminal kinase, demonstrating significant anti-inflammatory effects. SC-236 has been shown to reduce ERK phosphorylation in murine models, highlighting its potential for investigating inflammatory pathways and therapeutic interventions.
  2. COX-2 Inhibitor

    Humulone, a prenylated phloroglucinol derivative, is a selective inhibitor of cyclooxygenase-2 (COX-2). It demonstrates significant anti-inflammatory properties and serves as a positive modulator of GABAA receptors at low micromolar concentrations. Additionally, Humulone is known to inhibit bone resorption and exhibits antioxidant, anti-angiogenic, and pro-apoptotic activities, making it valuable for various research applications in inflammation and cancer studies.
  3. COX-2 Inhibitor

    DuP-697 is a potent, irreversible, and selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 10 nM for human COX-2 and 800 nM for COX-1. This compound demonstrates significant antiproliferative effects on HT29 colorectal cancer cells with an IC50 of 42.8 nM, as well as antiangiogenic and pro-apoptotic activities. By inhibiting prostaglandin synthesis, DuP-697 offers potential applications in studies related to inflammation, cancer, and fever reduction.
  4. COX Inhibitor

    Metamizole sodium is a potent cyclooxygenase (COX) inhibitor that exhibits significant anti-inflammatory, analgesic, and antipyretic properties. This compound not only inhibits cell proliferation but also promotes apoptosis in various cell types. Additionally, Metamizole sodium serves as a spasmolytic agent, making it a valuable tool for research applications aimed at pain relief and the study of inflammatory processes. Its multifunctional activities contribute to its utility in diverse areas of biomedical research.
  5. COX Inhibitor

    Ketorolac hemicalcium is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective cyclooxygenase (COX) inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in research related to allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain, as well as for its potential applications in cancer research due to its role as a DDX3 inhibitor.
  6. COX Inhibitor

    Metamizole magnesium is an orally active cyclooxygenase (COX) inhibitor known for its key roles in reducing inflammation and pain. It exhibits significant anti-inflammatory and antioxidant activities, along with the ability to inhibit cell proliferation and promote apoptosis. Due to its antipyretic and analgesic properties, Metamizole magnesium is commonly utilized in various research applications aimed at investigating pain mechanisms and inflammatory responses.
  7. Topo I/COX-2 Inhibitor

    Topo I/COX-2-IN-1 is an inhibitor of both Topoisomerase I and Cyclooxygenase-2 (COX-2). It demonstrates significant biological activity, with IC50 values of 0.24 μM for COX-2 and 4.42 μM for Topo I. This compound effectively induces apoptosis and inhibits the migration of cancer cells, showcasing potential applications in cancer research and therapy.
  8. Topo I/COX-2 Inhibitor

    Topo I/COX-2-IN-2 is a potent dual-target inhibitor of Topoisomerase I (Topo I) and Cyclooxygenase-2 (COX-2), exhibiting inhibitory concentrations (IC50) of 0.90 μM and 2.31 μM, respectively. This compound induces apoptosis in cancer cells via the mitochondrial pathway, making it a valuable agent for research in cancer therapeutics and cell death mechanisms. Its dual activity supports investigations into the interplay between topoisomerase inhibition and inflammatory pathways in cancer progression.
  9. COX-1 Inhibitor

    Ibuprofen sodium is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 13 μM. This compound demonstrates significant biological activities, including inhibition of cell proliferation, angiogenesis, and induction of apoptosis. As a nonsteroidal anti-inflammatory agent and nitric oxide (NO) donor, ibuprofen sodium is valuable in research areas such as pain, inflammation, infection, immunology, and oncology.
  10. COX-2 Inhibitor

    COX-2-IN-43 is a selective COX-2 inhibitor with an IC50 of 0.247 μM for COX-2 and 0.983 μM for COX-1. This compound demonstrates significant biological activity by inhibiting cancer cell proliferation and colonization while inducing apoptosis. It is valuable for research applications targeting inflammatory diseases and cancer therapeutics.
  11. COX Inhibitor

    Metamizole hemimagnesium is a cyclooxygenase (COX) inhibitor with anti-inflammatory and antioxidant properties. This compound effectively reduces body temperature and has been shown to decrease levels of C-reactive protein (CRP) and interleukin 6 (IL-6). Metamizole hemimagnesium also inhibits cell proliferation and promotes apoptosis. It is utilized in research applications focused on inflammation and fever modulation.
  12. COX Inhibitor

    Ketorolac hydrochloride is a non-steroidal anti-inflammatory drug (NSAID) that acts as a nonselective inhibitor of cyclooxygenase (COX), with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. It is utilized in the study of various ophthalmic conditions, including allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Additionally, Ketorolac hydrochloride functions as a DDX3 inhibitor, making it relevant for cancer research applications.
  13. COX Inhibitor

    Meloxicam sodium is a selective cyclooxygenase (COX) inhibitor, primarily targeting COX-2 with an IC50 of 0.49 μM while exhibiting a higher IC50 of 36.6 μM for COX-1. This non-steroidal anti-inflammatory agent is capable of crossing the blood-brain barrier, making it suitable for research applications involving central nervous system inflammation and pain management. Meloxicam sodium is widely utilized in studies assessing the efficacy of anti-inflammatory therapies.
  14. COX-1/2 Inhibitor

    Taraxerol acetate is an inhibitor of COX-1 and COX-2, exhibiting IC50 values of 116.3 μM and 94.7 μM, respectively. This compound demonstrates notable anticancer properties and has been shown to induce apoptosis in cancer cells. Taraxerol acetate is valuable for research applications focusing on inflammation, pain relief, and cancer treatment mechanisms.
  15. COX-2/NLRP3 Inhibitor

    COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions.
  16. COX Inhibitor

    (±)-Aiphanol is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-1 (IC50 = 1.9 μM) and COX-2 (IC50 = 9.9 μM). This compound displays significant anti-inflammatory properties and further inhibits vascular endothelial growth factor receptor 2 (VEGFR2) with an IC50 of 0.92 μM. By impeding both COX-2 and VEGFR2 pathways, (±)-Aiphanol effectively blocks angiogenesis and induces apoptosis, making it a valuable tool in the study of inflammatory diseases and cancer research. The compound demonstrates oral bioactivity, enhancing its potential for in vivo applications.
  17. COX Inhibitor

    Indomethacin farnesil is a prodrug of indomethacin, primarily targeting cyclooxygenase (COX) enzymes. This potent, blood-brain barrier-permeable inhibitor exhibits nonselective activity against COX-1 and COX-2, with IC50 values of 18 nM and 26 nM, respectively. Indomethacin farnesil has been shown to disrupt autophagic flux by impairing lysosomal function, making it useful for investigating inflammatory pathways and autophagy-related processes in research applications.
  18. COX-2 Inhibitor/PPAR-γ Activator

    Zaltoprofen sulfoxide is a selective COX-2 inhibitor with an IC50 of 45.38 nM, as well as a PPAR-γ activator. This compound effectively inhibits NF-κB and MAPK inflammatory signaling pathways, making it a valuable tool in the study of inflammation and acute lung injury models. It is particularly relevant for research focused on LPS-induced acute lung injury.
  19. COX-2 Inhibitor

    Hexahydrocurcumin is a selective, orally active inhibitor of cyclooxygenase-2 (COX-2), demonstrating significant potential in anti-inflammatory applications. As one of the primary metabolites of curcumin, it exhibits antioxidant and anticancer properties, making it relevant for research in various therapeutic areas. Its selectivity towards COX-2 over COX-1 highlights its potential for minimizing gastrointestinal side effects often associated with non-steroidal anti-inflammatory drugs (NSAIDs).
  20. COX-2 Inhibitor

    COX-2-IN-65 is a selective inhibitor of cyclooxygenase-2 (COX-2) with a reported IC50 of 10.24 μM. This compound exhibits antibacterial activity against Staphylococcus aureus and Escherichia coli, while also scavenging reactive oxygen species (ROS). COX-2-IN-65 is valuable for research applications focused on bacterial infections and inflammation pathways.
  21. iNOS/COX-2 Inhibitor

    Ermanin is a flavonoid extracted from Tanacetum microphyllum, known for its potent inhibitory effects on inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Its biological activities include anti-inflammatory, anti-tuberculous, and anti-viral/bacterial properties, making it a valuable reagent in research related to inflammation and infectious diseases. Ermanin is useful for exploring the pathways associated with nitric oxide production and prostaglandin synthesis in various biological contexts.
  22. COX Inhibitor

    α-Spinasterol is a selective inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 16.17 μM and 7.76 μM, respectively. This compound demonstrates a range of biological activities, including antibacterial, anti-inflammatory, antidepressant, and antioxidant effects. Furthermore, it can effectively cross the blood-brain barrier and has shown potential in improving diabetes in murine models, making it a valuable tool for research in inflammatory disorders and neurological conditions.
  23. COX-1/2 Inhibitor

    2-(p-Tolyl)propanoic acid is a selective inhibitor of COX-1 and COX-2 enzymes, displaying IC50 values of 38.23 μM and 64.30 μM, respectively. This compound exhibits antimicrobial properties and is relevant for research on bacterial pathogens such as Escherichia coli, Enterococcus faecalis, Listeria monocytogenes, and Staphylococcus aureus. Its mechanism of action positions it as a valuable tool for investigating inflammatory processes and antimicrobial resistance in various biological studies.
  24. COX Inhibitor

    Aspirin DL-lysine is a lysine-conjugated derivative of aspirin that functions primarily as a cyclooxygenase (COX) inhibitor. This compound effectively inhibits the synthesis of thromboxane A2 (TXA2) in platelets, leading to a reduction in platelet activation and aggregation. Aspirin DL-lysine is valuable for research applications focused on thrombin generation, particularly in clinical studies involving unstable angina pectoris.
  25. COX-2/Carbonic Anhydrase Inhibitor

    Polmacoxib is a novel, orally active nonsteroidal anti-inflammatory drug (NSAID) that acts as a dual inhibitor of cyclooxygenase-2 (COX-2) and carbonic anhydrase, with an IC50 value of approximately 0.1 μg/ml for COX-2. It exhibits significant biological activity by inhibiting the growth of colorectal adenomas and tumors in mouse models, making it a promising tool for cancer research. Polmacoxib is valuable for studying the roles of COX-2 and carbonic anhydrase in cancer biology and inflammation.
  26. COX-2 Inhibitor

    COX-2-IN-30 is a benzenesulfonamide derivative that functions as a potent selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 49 nM and also inhibits 5-lipoxygenase (5-LOX) with an IC50 of 2.4 μM. Additionally, it affects human carbonic anhydrase isoforms IX and XII, displaying nanomolar Ki values. This compound demonstrates significant analgesic and anti-inflammatory properties while maintaining a favorable gastrointestinal safety profile, making it useful for research in inflammation, pain relief, and related gastrointestinal studies.
  27. COX-2 Inhibitor

    APHS is a selective and covalent inhibitor of cyclooxygenase-2 (COX-2) that exerts neuroprotective effects. By acetylating serine 516 in the active site of COX-2, APHS effectively inhibits prostaglandin production, which is often upregulated in colorectal cancer. In addition to its role as a COX-2 inhibitor, APHS also co-inhibits the WNT signaling pathway, contributing to its anti-tumor mechanisms. This compound is valuable for research into cancer biology and neuroprotection.
  28. 5-LO/COX-2/DPP-4 Inhibitor

    Timosaponin A1 is a natural steroidal saponin that acts as an inhibitor of 5-lipoxygenase (5-LO), cyclooxygenase-2 (COX-2), and dipeptidyl peptidase 4 (DPP-4), with IC50 values of 3.29 µM, 36.43 µM, and 33.25 µM, respectively. This compound exhibits anti-inflammatory properties and is relevant for research on conditions such as asthma and diabetes. Its inhibitory effects on key enzymes involved in inflammatory pathways make it a valuable tool for exploring therapeutic strategies in related biological studies.
  29. COX-2 Inhibitor

    Thymohydroquinone is a selective inhibitor of cyclooxygenase-2 (COX-2) with noted anti-SARS-CoV-2 activity. It exhibits cytotoxic properties, antiproliferative effects, and the ability to suppress tumor growth in various cancer models. This compound is applicable in research focused on squamous cell carcinoma, fibrosarcoma, and the pathogenesis and treatment of COVID-19 caused by SARS-CoV-2.
  30. COX1/2 Inhibitor

    Indomethacin sodium is a potent inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 18 nM and 26 nM, respectively. This compound demonstrates significant anticancer and anti-infective properties, making it valuable in various biological research applications. Indomethacin sodium is essential for investigating mechanisms related to cancer treatment, inflammation, and viral infections.
  31. COX-1 Inhibitor

    NCX 466 is a selective inhibitor of COX-1 and COX-2, demonstrating notable anti-inflammatory and analgesic properties. It functions as a nitric oxide (NO) donor, enhancing microcirculation while exerting antioxidant effects. NCX 466 effectively reduces levels of transforming growth factor-β (TGF-β) and oxidative stress markers, including thiobarbituric acid reactive substances (TBARS) and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Furthermore, it mitigates leukocyte recruitment during inflammatory responses by decreasing myeloperoxidase (MPO) activity, contributing to the prevention of bleomycin-induced pulmonary fibrosis in murine models.
  32. COX-2 Inhibitor

    Hirsutanonol, a diarylheptanoid derived from the bark of Alnus hirsute var. sibirica, functions primarily as an inhibitor of cyclooxygenase-2 (COX-2). This compound exhibits significant anti-filarial activity, demonstrated by an IC50 value of 44.11 μg/mL against microfilariae. Hirsutanonol is valuable in research focused on inflammation reduction and parasitic disease interventions.
  33. COX-1 Inhibitor

    Dihydroflavokawin B is a selective COX-1 inhibitor, exhibiting an IC50 of 1.22 μM, with moderate effects on COX-2 and 5-LOX. This compound demonstrates significant activity against the promastigote forms of Leishmania panamensis and Leishmania braziliensis, making it a valuable tool for leishmaniasis research. Additionally, Dihydroflavokawin B inhibits rabbit platelet aggregation induced by arachidonic acid, platelet-activating factor, and adenosine diphosphate, highlighting its potential for in vitro anti-inflammatory studies.
  34. COX Inhibitor

    Serratiopeptidase is a zinc-containing metalloprotease that primarily acts as a cyclooxygenase (COX) inhibitor. It effectively reduces the release of inflammatory mediators such as prostaglandins and interleukins, alleviating pain and swelling. In addition to its anti-inflammatory properties, Serratiopeptidase exhibits mucolytic, antibiofilm, and wound-healing activities. Its enzymatic action allows it to dissolve fibrin and blood clots, while also demonstrating potential anti-Alzheimer's effects by degrading amyloid fibrils. Furthermore, Serratiopeptidase shows cytotoxicity against colon cancer cells, making it a versatile reagent for research applications in inflammation and oncology.
  35. COX Inhibitor

    Ibuprofen Impurity F is a specific impurity of Ibuprofen, a well-known anti-inflammatory compound that inhibits cyclooxygenase enzymes COX-1 and COX-2. It exhibits inhibitory activity with IC50 values of 13 μM for COX-1 and 370 μM for COX-2. This reagent is valuable for quality control and analytical characterization in pharmaceutical research and development, particularly in the study of non-steroidal anti-inflammatory drugs (NSAIDs).
  36. COX Inhibitor

    Piroxicam cinnamate is a cyclooxygenase (COX) inhibitor with demonstrated anti-inflammatory properties. It is stable under gastric conditions, making it suitable for research applications focused on inflammatory-degenerative osteoarticular diseases, rheumatic disorders, and varicocele-associated oligoasthenospermia. This compound offers significant potential for investigating therapeutic approaches to various inflammatory conditions.
  37. COX-1 Inhibitor

    Valeryl salicylate is a potent and irreversible inhibitor of cyclooxygenase-1 (COX-1). This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammatory processes. Its mechanism offers insights into the modulation of COX-1 enzyme activity and potential therapeutic applications in inflammatory conditions.
  38. COX1/2 Inhibitor

    4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone is a selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). This compound demonstrates significant anti-inflammatory properties and is valuable in research aimed at understanding the role of COX enzymes in various disease models. Its application extends to pharmacological studies focused on pain, inflammation, and potential therapeutic interventions.
  39. COX Inhibitor

    Ibuprofen impurity 1 is an impurity of the widely used anti-inflammatory agent ibuprofen, which acts as a dual inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 13 μM and 370 μM, respectively. This compound is essential for evaluating the purity and quality of ibuprofen formulations in research. It serves as a valuable tool for studying the pharmacological effects and potential side effects of ibuprofen in various biological assays.
  40. COX-2 Inhibitor

    Robenacoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with potent anti-inflammatory and analgesic properties. It primarily reduces the production of prostaglandins associated with inflammation and pain, making it valuable for research related to inflammatory diseases and pain management. This compound is utilized in studies aiming to elucidate the role of COX-2 in various biological processes and to develop therapeutic strategies targeting inflammation.
  41. COX-2 Inhibitor

    3-Carene is a bicyclic monoterpene that functions as a cyclooxygenase-2 (COX-2) inhibitor. It demonstrates significant anti-inflammatory properties by reducing nociceptive stimulus-induced inflammatory infiltrates and decreasing COX-2 overexpression. Additionally, 3-Carene enhances both the activity and expression of alkaline phosphatase, a crucial early marker of osteoblastic differentiation, making it a valuable compound for research in pain management and bone health.
  42. COX-2 Inhibitor

    Mavacoxib is a selective, oral cyclooxygenase-2 (COX-2) inhibitor, functioning as a long-acting non-steroidal anti-inflammatory drug (NSAID). This compound effectively alleviates pain and inflammation related to degenerative joint disease, particularly in canine subjects. Research applications include studies on inflammation and pain management in veterinary medicine.
  43. COX-2 Inhibitor

    Desmethyl Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 32 nM, demonstrating significant anti-inflammatory activity. As an analog of Celecoxib, this compound serves as a valuable tool in research applications focusing on inflammation and pain pathways. Its potency and specificity make it suitable for studies related to COX-2 mediated processes.
  44. 5-LO/COX Inhibitor

    BW 755C is a dual inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase (COX) enzymes, exhibiting an IC50 of 5 μM for 5-LO. It also demonstrates inhibitory activity against COX-1 and COX-2, with IC50 values of 0.65 and 1.2 μg/mL, respectively. This compound is valuable for research applications involving inflammation and other related pathways. Its ability to concurrently inhibit key lipid mediators makes BW 755C a useful tool in studies focused on arachidonic acid metabolism and signaling pathways.
  45. COX-2 Inhibitor

    Enflicoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory pathway. This nonsteroidal anti-inflammatory compound exhibits notable anti-inflammatory, analgesic, and antipyretic effects in various animal models. Enflicoxib is valuable for research investigating COX-2-mediated processes and potential therapeutic applications in pain management and inflammation.
  46. COX-1 Inhibitor

    CP-74006 is a selective inhibitor of Cyclooxygenase-1 (COX-1). This compound demonstrates significant anti-inflammatory activity by blocking the conversion of arachidonic acid to prostaglandins, key mediators in the inflammatory response. CP-74006 is utilized in research focusing on inflammation, pain management, and cardiovascular disease, providing valuable insights into COX-1 related biological processes.
  47. COX inhibitor

    2-Chloro-N-(2,6-dimethylphenyl)acetamide is a cyclooxygenase (COX) inhibitor that modulates inflammatory responses by inhibiting the conversion of arachidonic acid to prostaglandins. Its biological activity makes it a valuable tool in research focused on inflammation and pain pathways. This compound is utilized for studying COX-related mechanisms in various biological contexts, potentially aiding in the development of anti-inflammatory therapies.
  48. COX- 2 Inhibitor

    Ocarocoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 1.4 μM. By inhibiting COX-2, Ocarocoxib effectively reduces the synthesis of prostaglandins, thereby imparting significant anti-inflammatory effects. This compound is useful for research on inflammation and associated pathological conditions.
  49. COX-2/5-LOX Inhibitor

    Tebufelone is a selective dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO). It exhibits significant anti-inflammatory, analgesic, and antipyretic properties, making it useful for research into inflammatory pathways. This compound is valuable for studying the roles of COX-2 and 5-LO in various biological processes and assessing novel therapeutic strategies for inflammatory diseases.
  50. COX-1 Inhibitor

    Teriflunomide impurity 3, also known as 4-Amino-N-(4-trifluoromethylphenyl)benzamide, acts as a selective inhibitor of cyclooxygenase-1 (COX-1) with an IC50 of 30 µM. This compound exhibits significantly lower activity against COX-2, with an IC50 greater than 100 µM. Teriflunomide impurity 3 is valuable for research applications exploring inflammatory pathways and the role of COX-1 in various biological processes.

Items 101-150 of 317

Page
per page
Set Descending Direction